{
    "nct_id": "NCT04082364",
    "official_title": "A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer",
    "inclusion_criteria": "* Histologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic HER2+ GC or GEJ adenocarcinoma\n\n  1. Prior systemic perioperative treatment is allowed; however the participants must have had a disease-free interval of at least 6 months from end of chemo/surgery\n  2. Participants receiving perioperative anti-HER2 therapy require testing of HER2 status for eligibility\n  3. Cohort A: HER2-positive (by IHC 3+) and PD-L1-positive (by IHC with 22C3 CPS ≥ 1%) per central review\n  4. Cohort B: HER2-positive (by IHC 3+ or IHC 2+ in combination with FISH+) by local review. PD -L1 status is not required for enrollment.\n* Availability of formalin-fixed, paraffin-embedded tumor specimen, unstained slides or contemporaneous biopsy for tumor target testing\n* Eastern Cooperative Oncology Group performance status of 0 or 1, verified within 3 days of Day 1\n* Life expectancy ≥ 6 months\n* At least one radiographically measurable target lesion\n* Acceptable laboratory parameters and adequate organ function\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Other malignancy that is progressing or required treatment within the past 5 years, with certain exceptions\n\n  * Participants with known MSI-H status\n* History of allogeneic stem cell or tissue/solid organ transplant\n* Central nervous system metastases\n* Clinically significant cardiovascular disease, gastrointestinal disorders, pulmonary compromise\n\n  * Prior neoadjuvant or adjuvant treatment with immunotherapy",
    "miscellaneous_criteria": "Key"
}